Medication Prescribing

The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...

The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...

The FDA has expanded the approval a new option for the treatment of adults and children aged 12 years and older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...

The FDA has approved Jynneos, a new live, non-replicating vaccination for the prevention of smallpox and monkeypox in adults aged 18 years and older who are at high risk for the diseases.

The FDA has approved the first glucagon-like peptide receptor protein treatment in the US that is not given via injection.

An FDA advisory committee has recommended the approval of the first therapy for peanut allergies.

An FDA advisory committee has recommended the approval of the first therapy for peanut allergies.

An FDA advisory committee has recommended the approval of the first therapy for peanut allergies.

The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.

The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.